Literature DB >> 20064824

Implications of body mass index in Japanese patients with prostate cancer who had undergone radical prostatectomy.

Atsushi Komaru1, Naoto Kamiya, Hiroyoshi Suzuki, Takumi Endo, Makoto Takano, Masashi Yano, Koji Kawamura, Takashi Imamoto, Tomohiko Ichikawa.   

Abstract

OBJECTIVE: To determine the association between obesity and prostate cancer in Japanese recurrence after primary treatment with radical prostatectomy.
METHODS: The subjects were 173 Japanese patients with prostate cancer who had been treated with radical prostatectomy at Chiba University Hospital between April 1997 and March 2007. Clinicopathological characteristics and biochemical recurrence outcomes after radical prostatectomy were compared between the three body mass index cohorts.
RESULTS: Mean body mass index was 23.4 kg/m(2) with a standard deviation of 2.4, and mean follow-up period was 37.4 months. Operative time was longer and estimated blood loss was much more in obese patients. Patients with pT3>or= had significantly higher serum prostate-specific antigen, total cholesterol levels, Gleason's sum and positive of surgical margin than pT2 patients. Recurrence rate was significantly higher in the 26.5 kg/m(2) and hyperlipidemia groups in pT3>or= patients.
CONCLUSIONS: Obesity is an independent predictor of disease recurrence in Japanese patients with pT3>or= prostate cancer who underwent radical prostatectomy. Obese patients who underwent radical prostatectomy require vigilant follow-up care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20064824     DOI: 10.1093/jjco/hyp164

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort.

Authors:  L C Macleod; L J Chery; E Y C Hu; S B Zeliadt; S K Holt; D W Lin; M P Porter; J L Gore; J L Wright
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-03-31       Impact factor: 5.554

2.  Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era.

Authors:  Corinne E Joshu; Alison M Mondul; Andy Menke; Cari Meinhold; Misop Han; Elizabeth B Humphreys; Stephen J Freedland; Patrick C Walsh; Elizabeth A Platz
Journal:  Cancer Prev Res (Phila)       Date:  2011-02-16

Review 3.  Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients.

Authors:  Mario Rivera-Izquierdo; Javier Pérez de Rojas; Virginia Martínez-Ruiz; Miguel Ángel Arrabal-Polo; Beatriz Pérez-Gómez; José Juan Jiménez-Moleón
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-06       Impact factor: 5.455

4.  Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels.

Authors:  Keisuke Goto; Hirotaka Nagamatsu; Jun Teishima; Yuki Kohada; Shinsuke Fujii; Yoshimasa Kurimura; Koji Mita; Masanobu Shigeta; Satoshi Maruyama; Yoji Inoue; Mitsuru Nakahara; Akio Matsubara
Journal:  Mol Clin Oncol       Date:  2017-04-10

5.  Advantages of robot-assisted laparoscopic radical prostatectomy in obese patients: comparison with the open procedure.

Authors:  Jae Jun Bae; Seock Hwan Choi; Seok Hwan Choi; Tae Gyun Kwon; Tae-Hwan Kim
Journal:  Korean J Urol       Date:  2012-08-16

6.  Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis.

Authors:  Pei-De Bai; Meng-Bo Hu; Hua Xu; Wen-Hui Zhu; Ji-Meng Hu; Tian Yang; Hao-Wen Jiang; Qiang Ding
Journal:  World J Surg Oncol       Date:  2015-11-05       Impact factor: 2.754

7.  Influence of serum total cholesterol, LDL, HDL, and triglyceride on prostate cancer recurrence after radical prostatectomy.

Authors:  Sheng Cheng; Qiming Zheng; Guoqing Ding; Gonghui Li
Journal:  Cancer Manag Res       Date:  2019-07-16       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.